Three Trans-Tasman Stocks for Reporting Season

Why It Matters

The upgrades and capital moves signal renewed investor confidence in New Zealand’s health, telecom and energy firms, while highlighting macro‑economic sensitivities that could shape the region’s market momentum.

Key Takeaways

• FPH forecasts $2.3bn revenue, $450‑470m profit.
• NZ dollar weakness boosts FPH export competitiveness.
• Chorus fibre penetration reaches 72%, displacing copper.
• Genesis seeks $400m raise, government support critical.
• NZ housing remains soft, telecoms face headwinds.

Pulse Analysis

Fisher & Paykel Healthcare’s revised guidance underscores how currency dynamics can amplify corporate performance. A depreciating New Zealand dollar lowers the effective price of its medical devices overseas, strengthening margins and justifying the higher profit range. Coupled with the recent U.S. tariff adjustments, the net effect for trans‑Tasman exporters remains balanced, but the immediate currency boost offers a clear short‑term catalyst that investors are rewarding with a near‑5% share rally.

In the telecommunications arena, Chorus is capitalising on a decisive shift toward fibre optics. With 72% of the market now connected to high‑speed fibre, the company enjoys a robust pipeline of upgrades and new installations, reducing reliance on legacy copper infrastructure. This transition not only improves service quality for consumers but also positions Chorus to capture higher‑margin data services, a critical growth vector as remote work and streaming demand intensify across the region.

Genesis Energy’s $400 million capital raise illustrates the strategic role of government backing in New Zealand’s energy sector. The funding will support infrastructure projects and renewable investments, aligning with the country’s decarbonisation targets. By mirroring Contact Energy’s financing move, Genesis signals confidence in its balance sheet and future cash flows, while the public‑sector endorsement mitigates investor risk. Together with the broader, albeit tentative, economic recovery, these developments highlight how sector‑specific catalysts and policy support are shaping the outlook for trans‑Tasman equities.

Original Description

Fisher & Paykel Healthcare (ASX:FPH) has captured market attention following an upgrade to its earnings guidance, with operating revenue now expected to reach $2.3 billion and operating profit projected between $450 million and $470 million. Greg Smith from Generate KiwiSaver points to a weaker Kiwi dollar as a key tailwind for the healthcare giant, whose shares have surged nearly 5%, accounting for approximately 15% of the local index. Smith highlights that while global tariff changes, particularly those increased by Trump to 15%, initially spurred optimism, their ultimate impact remains net neutral for New Zealand exporters compared to Australia.

Turning to other sectors, Smith notes mixed results to the earnings season. Chorus (ASX:CNU) is benefiting from steady demand for fibre uptake, with 72% penetration as users shift away from copper. In the energy sector, Genesis Energy’s (ASX:GNE) planned $400 million capital raise follows on the heels of a similar move by Contact Energy, with government backing of Genesis cited as significant for the success of the raise.

Smith observes that US trade policy developments provide some near-term certainty, but also inject further uncertainty into global markets. Locally, New Zealand’s recovery is still in its early stages, with the housing market proving soft and sectors like telecommunications and casinos navigating ongoing headwinds.